[Decreased need for tablets with pantoprazole. PPI: independent study questions savings through use of generic drugs].
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage / Q000191:economics*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics*; D017046:Cost Savings / Q000331:legislation & jurisprudence; D004305:Dose-Response Relationship, Drug; D016527:Drug Costs / Q000331:legislation & jurisprudence*; D016568:Drugs, Generic / Q000008:administration & dosage / Q000191:economics*; D005764:Gastroesophageal Reflux / Q000188:drug therapy / Q000191:economics*; D005858:Germany; D006801:Humans; D009313:National Health Programs / Q000191:economics*; D000077402:Pantoprazole; D054328:Proton Pump Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics*; D013607:Tablets; D013810:Therapeutic Equivalency
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D016568:Drugs, Generic; D054328:Proton Pump Inhibitors; D013607:Tablets; D000077402:Pantoprazole